BioPharmSignal logoBioPharmSignal

Biotech News

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Spero Therapeutics (SPRO)Spero TherapeuticsClinical readout

Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases

Appointment strengthens Spero's clinical leadership team as the Company advances SP001, a Phase 2-ready third-generation anti-CD40L antibody for IgG4-related disease...

Related news

SPROSpero Therapeutics2026-07-14 11:00 EST

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

ANTXAN2 Therapeutics2026-11-04 12:00 EST

AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)

ANTXAN2 Therapeutics2026-10-21 11:00 EST

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

SPROSpero Therapeutics2026-11-04 22:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AVIRAtea2026-07-14 11:00 EST

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

SCYXSCYNEXIS2026-10-22 12:00 EST

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

SCYXSCYNEXIS2026-10-06 11:30 EST

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

IMNNImunon2026-06-22 20:15 EST

IMUNON to Present at the Life Sciences Investor Forum on June 25th

ENTAEnanta Pharmaceuticals2026-10-26 11:00 EST

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

IMNNImunon2026-07-21 13:00 EST

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

View all latest news

Spero Therapeutics

Immunology and Inflammation Company Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases. Its internal strategy now centers on CD40 ligand inhibition. SP001 SP001 is a third-generation, Fc-silent monoclonal antibody targeting CD40 ligand. The molecule is designed to...

Recent company news

SPROSpero Therapeutics2026-11-04 22:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SPROSpero Therapeutics2026-11-02 22:05 EST

Spero Therapeutics to Present at Investor Conferences in November

SPROSpero Therapeutics2026-10-26 13:00 EST

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

SPROSpero Therapeutics2026-10-26 13:00 EST

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

SPROSpero Therapeutics2026-10-26 13:00 EST

Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline

Stock data

Close
1.02 USD
Market cap
163.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States